VX-787 is an investigational medicine being developed by Vertex that is designed to directly inhibit replication of influenza A, including recent H1 (pandemic) and H5 (avian) influenza strains, based on in-vitro data. VX-787's mechanism represents a new class of potential medicines for the treatment of influenza, distinct from neuraminidase inhibitors, the current standard of care for the treatment of influenza. VX-787 is intended to provide a rapid onset of action and an expanded treatment window. VX-787, which was discovered by Vertex scientists, underscores the Company’s expertise in antiviral drug development, beginning with early research in HIV and more recently in hepatitis C. Vertex has worldwide rights to develop and commercialize VX-787.
Each year in the U.S., more people die from influenza than die from HIV/AIDS. i Often called “the flu,” seasonal influenza is caused by influenza viruses, which infect the respiratory tract. ii The flu can result in seasonal epidemics iii and can produce severe disease and high mortality in certain populations, such as the elderly. iv Each year, on average 5 to 20 percent of the U.S. population gets the flu v resulting in more than 200,000 flu-related hospitalizations and 36,000 deaths. vi The overall national economic burden of influenza-attributable illness for adults is $83.3 billion. vi Direct medical costs for influenza in adults totaled $8.7 billion including $4.5 billion for adult hospitalizations resulting from influenza-attributable illness. vi The treatment of the flu consists of antiviral medications that have been shown in clinical studies to shorten the disease and reduce the severity of symptoms if taken within two days of infection. vii There is a significant need for new medicines targeting flu that provide a wider treatment window, greater efficacy and faster onset of action.About Vertex Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.